Pfizer COVID-19 Vaccines Results
Encouraging, Early Test Results Of Pfizer & BioNtech’s COVID-19 Vaccine Candidates Reported
The American multinational pharmaceutical corporation, Pfizer, headquartered in New York City and its German partner BioNTech said that they recorded encouraging results in very early testing of 45 people in the first of their four experimental COVID-19 vaccines.
According to the preliminary results, when compared to some COVID-19 survivors, the study volunteers had immune responses in the range expected to be protective when they were given either a low or medium dose, in two shots about a month apart. Mostly fever and pain at the injection site, the sides effects typical for vaccines were observed.
The report is yet to be reviewed and it has been submitted for publication in a scientific journal.
Pfizer aims to open a large-scale study this summer but can’t yet say which shot is best to include, with its other potential candidates still in the earliest stage of testing. In order to prime the body to recognize and attack the virus, a piece of the coronavirus genetic code is made used by the vaccine candidates by Pfizer and BioNTech.
But researchers were sticking with the low and medium doses and did not administer a second shot of the highest dose initially tested. More injection reactions without apparent added benefit were caused by the higher-dose shot.
Globally, there are over 15 different COVID-19 vaccine candidates in human testing currently. Although there’s no guarantee, different companies are proceeding with different types of vaccines, boosting the odds that at least one approach might work against the global pandemic of a novel coronavirus, COVID-19 caused by the SARS-CoV-2 virus.
Encouraging, Early Test Results Of Pfizer & BioNtech’s COVID-19 Vaccine Candidates Reported in very early testing of 45 people in the first of their four experimental COVID-19 vaccines.
